Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress | Business Wire
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
Sage Therapeutics surges 70% after depression drug breakthrough
sage-10k_20161231.htm
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
Keeping up with the clinical advances: depression | CNS Spectrums | Cambridge Core
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
Sage shares up after FDA allows expedited depression drug development
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder | Business Wire
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
Sage Therapeutics and Biogen Report Positive Phase 3 Data Showing Zuranolone Significantly Reduced Depressive Symptoms After Two Weeks
Here's Why Sage Therapeutics Rose as Much as 20.3% Today | The Motley Fool
Zuranolone - Wikipedia
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder - Chemdiv
Bait and Switch: the Great Ketamine “Breakthrough” | RxISK
Sage Therapeutics Reports Positive Top-Line Results from Phase II Placebo-Controlled Trial of SAGE-217 in MDD - Drug Discovery and Development
Sage Therapeutics' SAGE-217 Receives FDA's Breakthrough Designation for CNS Disorders
Sage Therapeutics Forges $575 Million Deal With Shionogi to Market Depression Drug in Parts of Asia | BioSpace
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
sage-10k_20161231.htm
Sage Therapeutics Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder Does Not Meet
Sage surges after depression drug gets rapid path to approval - PMLiVE
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
SAGE Therapeutics shares rocket after FDA clearance to expedite its depression post-partum drug SAGE-217
Emboldened By Sage's Zulresso Slip, Marinus Is Set To Succeed In PPD And Orphan Epilepsy (NASDAQ:MRNS) | Seeking Alpha
Sage Therapeutics Announces Promising Zuranolone Phase 3 Findings for Major Depression
